Company intelligence / Profile preview

Viela Bio

Gaithersburg, Maryland, USAorpha.net ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

UPLIZNA® (inebilizumab-cdon), Viela Bio's lead asset, received FDA approval for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-AQP4 antibody positive. The company had four therapeutic candidates across nine development programs targeting autoimmune and severe inflammatory diseases at the time of its acquisition by Horizon Therapeutics.

Therapeutic areas: Neurology
Modalities: Monoclonal antibodiesBiologics
Industry: Biotech

Drug pipeline

4 assets

inebilizumab

Commercial

Indications: Neuromyelitis optica spectrum disorder, Myasthenia gravis, IgG4-related disease

3 more assets in the full pipeline.

Request access →

Partnerships

AstraZenecaMedImmune

Beyond the preview

Go deeper on Viela Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viela Bio.

Explore the full profile